Core Insights - Small nucleic acid drugs are emerging as potential leaders in the weight loss sector, shifting from merely "suppressing appetite" to "precisely regulating fat metabolism" [1][2] - The global weight loss market still has unmet needs despite the rapid uptake of GLP-1 drugs, which face issues such as rebound weight gain and gastrointestinal intolerance [2] - Domestic companies are quickly establishing small nucleic acid weight loss pipelines, focusing on targets, delivery platforms, and indications to unlock potential value in health weight loss and fatty liver disease [1][2] Group 1: INHBE Insights - INHBE, which encodes activin E, interacts with the ALK7 receptor in adipose tissue to inhibit fat breakdown, presenting a differentiated clinical value with strong drug development certainty [3] - Early clinical data for INHBE siRNA shows safety and efficacy in long-term fat loss while preserving muscle mass, with combined therapy yielding doubled weight loss and tripled visceral fat reduction compared to GLP-1 [3] - The GalNAc delivery system used for INHBE siRNA has proven clinical development certainty due to existing successful drugs like inclisiran [3] Group 2: ALK7 Insights - ALK7 siRNA requires a targeted delivery system to adipose tissue, with early clinical data indicating significant mRNA knockdown efficiency and sustained effects [4] - ARO-ALK7 demonstrated superior reduction in visceral fat compared to INHBE, with a 14.1% reduction observed at the 8-week mark after a single 200 mg dose [4] - The breakthrough in fat-targeted delivery systems is crucial for the competitive landscape of small nucleic acid drugs [4] Group 3: Investment Recommendations - Relevant investment targets include companies such as Heng Rui Medicine, Innovent Biologics, and others involved in small nucleic acid drugs [5] - The potential for small nucleic acid drugs in the weight loss market is significant, with various companies positioned to capitalize on this emerging trend [5]

Core Viewpoint - The pharmaceutical sector, particularly in innovative drugs, is experiencing a surge driven by significant clinical data in the small RNA weight loss field, leading to a notable increase in the STAR Market's innovative drug index and the corresponding ETF [1][3]. Group 1: Small RNA Weight Loss Data - Arrowhead Pharmaceuticals presented mid-stage data from its two small RNA weight loss projects, ARO-INHBE and ARO-ALK7, indicating a new paradigm in "high-quality weight loss" that focuses on visceral fat reduction rather than just weight loss [3][4]. - ARO-INHBE demonstrated a 9.4% weight loss in type 2 diabetes patients when combined with tirzepatide, significantly outperforming tirzepatide alone, which achieved a 4.8% reduction. Key metrics showed visceral fat reduction of 23.2%, total fat reduction of 15.4%, and liver fat reduction of 76.7%, approximately three times better than monotherapy [3][4]. - ARO-ALK7, the first RNAi therapy to validate fat cell gene knockdown effects in humans, achieved an average knockdown of 88% of ALK7 mRNA, with a maximum of 94%. After eight weeks of a single dose, visceral fat decreased by 14.1%, confirming the feasibility of targeting fat cell metabolic pathways [3][4]. Group 2: Significance of Visceral Fat Reduction - The ultimate goal of weight loss treatment is not merely the reduction of weight but the improvement of long-term cardiovascular, renal, and metabolic outcomes. Visceral fat, despite its low absolute quantity, is crucial as it surrounds vital organs and is linked to insulin resistance, fatty liver, and cardiovascular diseases [4]. - Effective reduction of visceral fat could significantly enhance metabolic status and lower the risk of long-term cardiovascular and renal events, providing higher clinical value for managing diabetes, obesity, and related complications [4]. Group 3: Synergy of Small RNA and GLP-1 - Current GLP-1 drugs are foundational in weight loss treatment but have unmet needs regarding visceral fat improvement, muscle loss, and rebound weight gain. The data suggests that small RNA drugs could complement fat metabolism pathways, enhancing the quality of weight loss rather than just the quantity [5]. - This validation of the synergistic logic between small RNA and GLP-1 strengthens market perception of the long-term value of the small RNA technology platform, leading to increased investment in high-research, innovative assets within the STAR Market [5]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for small RNA drugs, with significant growth and validation expected, including commercial progress for Plozasiran and larger sample data readouts for ARO-INHBE and ARO-ALK7 [6]. - The capital market may see small RNA companies listing on the Hong Kong stock exchange, further enhancing market focus on this niche sector as overseas RNAi technology matures and domestic pipelines advance [6]. Group 5: Investment Opportunities - Following a period of adjustment, the innovative drug sector's overall valuation has returned to historically low levels. With the upcoming release of high-quality data and international conference catalysts, funds may begin reallocating towards high-elasticity sectors with medium to long-term industrial logic [7]. - Investors are encouraged to monitor developments in high-quality clinical data and international business development progress, which could drive further capital back into the innovative drug sector, potentially leading to a phase of upward trends [8].